When combined with ipamorelin, MK-677 raises the floor while ipamorelin provides the pulse. However, somatostatin modulators are rarely used in research stacks because they risk disrupting the natural pulsatility that protects against receptor desensitization. Somatostatin is the endogenous peptide that inhibits GH release between pulses, ensuring GH secretion remains pulsatile rather than constant. Hexarelin is another potent secretagogue occasionally stacked with ipamorelin, though it carries the highest risk of desensitization. Typical protocols dose ipamorelin in the morning and GHRP-2 in the early afternoon, spaced 4–6 hours apart. The rationale for stacking within the same receptor class is half-life staggering. GHRP-2 and GHRP-6 are less selective than ipamorelin, meaning they activate additional pathways including cortisol and prolactin to varying degrees. HGH is only superior for clinical growth hormone deficiency or bodybuilding-level supraphysiological dosing goals. Unlike exogenous HGH (which injects synthetic growth hormone directly), secretagogues trigger your body's own GH production. A growth hormone secretagogue is any compound that stimulates the pituitary gland to release growth hormone. Growth hormone releasing peptides activate the GHS-R1a receptor (ghrelin/growth hormone secretagogue receptor) on the pituitary. GHRH analogs mimic growth hormone-releasing hormone — the hypothalamic signal that tells the pituitary to synthesize and prepare GH for release. Growth hormone secretagogues (GHSs) are compounds that stimulate the pituitary gland to produce and release its own growth hormone. Sermorelin is often compared to ipamorelin because both have clean side effect profiles. It does one thing (GH release) without triggering the cortisol, prolactin, or appetite stimulation that makes other GHRPs harder to use. The key differentiator — the thing that keeps people coming back to ipamorelin specifically — is selectivity. A study in Endocrinology found that co-administration of a GHRP and a GHRH analog produced GH release 3–5 times higher than the sum of each peptide administered alone, a phenomenon called synergistic amplification. Activating multiple pathways simultaneously doesn't just add their effects. This means it won't cross-activate pathways that control appetite (a common side effect of GHRP-6), stress hormones, or glucose metabolism. Ipamorelin has high selectivity for GHS-R1a with minimal affinity for GHS-R1b or other ghrelin-related receptors. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that ipamorelin at 1 mcg/kg produced mean GH elevation of 2.7-fold over baseline, compared to 4.2-fold with GHRP-6 at equivalent doses. Nobody disputes their naturalness, though even here the line is blurry because creatine in supplement form delivers doses far higher than any diet provides. The most important boundary on this spectrum is whether a compound suppresses your endogenous hormone production. Between those extremes exists a vast middle ground where the critical distinctions are not about whether you use anything, but about what you use and what it does to your body’s natural systems. These compounds appear to possess many of the same beneficial effects as those seen with GH therapy itself while demonstrating none of the same adverse side effects or regulatory concerns. GH therapy has been shown to improve lean body mass, decrease adiposity, and improve serum lipid profiles (16,17). These findings highlight the fact that although TTh can improve lean body mass and other essential metabolic parameters, it may not inhibit fat mass increases that are seen with metabolic syndrome. The authors also failed to observe changes in body weight, body mass index (BMI), or bone density (14). By mimicking ghrelin, ipamorelin selectively binds the same GHSR-1a receptor as GHRP-2, GHRP-6, and ibutamoren (55,56). These findings demonstrate that ibutamoren treatment can increase GH and IGF-1 levels for up to 2 years. The group that started ibutamoren during the second year saw the same changes while the group that switched to placebo in the second year saw a reversal of the changes induced by ibutamoren treatment in the first year. The original ibutamoren treatment group was separated into either a placebo or continued ibutamoren treatment group. Ibutamoren treatment did not affect FSH and LH levels, but did lead to decreased total testosterone levels with conserved free testosterone levels. The ibutamoren treatment group experienced a significant weight gain of 2.7 kg at 8 weeks, which decreased to a nonsignificant 1.8 kg weight gain 1 week after the end of treatment. Paralleling the Chapman et al. study, ibutamoren led to an elevation in serum prolactin at 2 and 8 weeks but no significant changes were observed in serum or urine cortisol. We recommend following these patients with regular examinations for changes in body composition and IGF-1 levels during GHS treatment, as well as with blood glucose and Hb A1c monitoring. In a 2-month trial of ibutamoren in 24 obese males, fasting glucose and insulin levels were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks(56). A large trial in Alzheimer’s patients found a more patients with increased blood glucose levels in the ibutamoren group (15.4%) than the placebo group (4.6%), with similar differences in HbA1c levels between the groups(65). In 32 healthy elderly patients, Chapman et al. observed that 25 mg of daily ibutamoren increased glucose concentrations by 25.3% and 26.9% above baseline at 2 and 4 weeks, respectively. Within the limits of current literature, growth hormone secretagogues appear safe, with few of the studies cited in this review observing serious adverse events (AEs) with the use of GHRPs. After one year, open label treatment for an additional 2 years demonstrated that the positive effects on body composition were maintained(57).
